Thank everyone call. current its and ischemia, acute pulmonary on are heart chronic afternoon good ischemic BioCardia's failure, platforms advancing you, respiratory allogeneic myocardial autologous and focused significant the on cell its unmet cardiovascular and efforts and distress therapy Miranda, treat to to diseases, syndrome. specifically
are monitoring CardiAMP that failure This curve of has thrown multiple programs therapeutic ball intend trial or third involve or All This the all enrollment with delivery to board where the the we them the in and pause were viable. recommended study. still safety of not heart of data BCDA-XX we mission therapies the for cell-based a locally. quarter, our we lungs to changed these act heart
randomized patients We study the have in Board Data were Safety recommendation the last followed October. the Monitoring and in
in physicians evaluating in follow-up clinical to to and both treatment group and October the We expect which in patients are enrolled monitor this blinded this XXXX. patients complete study study for continue in
patients have were to come aware successful, benefits have the understand were design We were with equivalent death of unlikely top we even endpoint become all in as across risk and on Adverse relative trial XX% the list. toward Cerebrovascular MACCE, risk at trends reduction we Cardiac XX% a strong heart to be which reduction an and that that Events, or Major are since the and there relative advancing,
levels to in trials. In patients eligible visit that were data the baseline subset reduction heart available addition, failure in the a well-established equivalent and be important biomarker increased of an screening with showed of note, heart for higher NT-proBNP even interim all trials the for where to presented elevated greater. NT-proBNP, patients current at death of to who the stress we in have MACCE leading require looked heart, Of these failure participate heart
volume distance Fraction, cell Left Questionnaire, of risk reduction In End-diastolic favored relative Failure these levels including Further, End patients, heart a included volume. reduction using and in Heart in of life XX% Living shows risk Minnesota parameters outcomes this of Ventricular analysis of with X-minute greater quality cardiac data clinical the Ventricular Ejection controls, MACCE. X measured including reduction mortality in Left Left of therapy, the relative as years available over improvements walk up analysis trial a NT-proBNP improved to improved an failure and Ventricular and XX% systolic all subset echocardiography all
available. initiated the of demonstrated and improved equivalents of death FDA endpoint with a FDA failure data, with statistically and higher interim a this patients therapy levels of heart different heart Because significant and quality X clinical data reduced the a protocol life utilizes which NT-proBNP subset on this the favoring proposed have in Both review for outcomes submitted targets analysis. we the based dialogue
of patients the population. clinical trial probability for sized modestly statistical XX% of is clinical that of this the study on Recent frame is data representative support success interim based design if power, results the for which a XXX another calculations would achieve
Additional for Medicare proposed heart execution to BioCardia, the possible design modifications the approved therapy study. and treatment site of from the control failure CardiAMP and of logistics by be trial costs of the now therapeutic study it clinical protocol in clinical performing may with be the simplify to study. reimbursement advanced investigational by arms to this place offset significantly cell elements both include reduce $XX,XXX the cost up and FDA the Should
also actively for CardiAMP PMDA, approval the on information answering have Medical indication based and Pharmaceutical been failure requests by on Device for heart safety ischemic towards and of data. an system We Japan's or cell efficacy therapy existing Agency,
are consultation Our scheduled for Subsequent XXXX. interactions PMDA expected. formal consultations is November XX, in with
The cell to cell CardiAMP potential therapy or up the ischemia controlled intended XXX myocardial patients for has available double-blinded The include also it's Phase sites. and therapy system cell a minimally Bcl-X up trial CardiAMP at clinical therapy III to randomized XX invasive be to first is study, Japan. multicenter chronic in catheter-based to
to therapy. treated underway place reimbursement therapeutic for includes Medicare this arms the randomization of for Planning planning the of the to expects in clinical the of leading rolling both experience Part based compelling of phase both this the including on this trial. principal most to in this treatment trial, The the enrollment control cohort quarter be indication fourth date. complete in in investigational of and utilizing patients this the the XXXX study that in begin the the to costs. investigators, offset for already A believe randomized X and company patients investigators promising of phase number is
failure treated BCDA-XX, serious have delivery adverse This heart we patients. The the ischemic cell therapy consented, company's using allogeneic with stem enrolling already a Helix intended clinical Phase patients trial for in study compelling previous first heart trials in early and ischemic the patients is treatment-emergent to and benefit. I/II failure cells proprietary on X no XX events anticipate or signals encompassing CardiALLO, for been A build company's is mesenchymal of system, fourth XX patients number of encompassing quarter.
here is strategy funding to program. and partnerships grant advance Our seek this to
its team can our BioCardia therapeutic through business delivery world-class meaningful is deals the and of Biotherapeutic System is year. that our Helix intramyocardial working active, biotherapeutics the capabilities are long-term Delivery close partnerships costs. delivery its and delivery by to help utilizing end Biotherapeutic towards opportunities for advance operational focusing multiple partnering base offset development we
confidence us. chronic and have myocardial of therapy cell based autologous program summary, ischemia the ischemic both have In we increased failure in on our in we before potential heart data CardiAMP in the
advancing and with and programs autologous already a System.
In Medicare support partner in with our have to fashion Delivery patients Helix our clinical our around we delivery coming the model allogeneic enrollment anticipate CardiAMP in FDA programs strategically working program therapy focused development experienced Biotherapeutic biotherapeutic and cell we recurring cell implementing benefit both of on allogeneic and world-class anticipate weeks, these on place.
Similarly, cash-neutral on the are from their the PMDA clinical our therapy grants our of feedback team revenue partnerships and program. in CardiALLO X are a securing We reimbursement we and
who now positive We our XXXX results. QX business pass David financial will also development review to will expect CFO, David? the activities.
I our news from McClung, call
